Mitchell Dowsett, PhD, on Estimating Residual Distant Recurrence Risk: EndoPredict and Oncotype DX
2015 San Antonio Breast Cancer Symposium
Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01).
Gunter von Minckwitz, MD
Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).
Clifford A. Hudis, MD, and Joseph A. Sparano, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Joseph A. Sparano, MD, of Montefiore Medical Center, discuss this study of high-risk premenopausal luminal A breast cancer patients receiving adjuvant chemotherapy (Abstract S1-08).
Lori J. Pierce, MD
Lori J. Pierce, MD, of the University of Michigan Health System, discusses findings on second cancer incidence and non-breast cancer mortality among 40,000 women in 75 clinical trials. (Abstract S5-08)
Patricia A. Ganz, MD
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).
Andrew Seidman, MD, and Hope S. Rugo, MD
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss the recent approval of a cooling cap to reduce hair loss during chemotherapy.